Cell and Gene Therapy

Gene therapy for inherited deafness free

Digest more

· 19h

New Gene Therapy Enables Children With a Rare Form of Deafness to Hear

The Food and Drug Administration on Thursday approved a gene therapy that can cure a rare, inherited form of deafness.

· 16h

'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness

· 18h

The FDA gives the green light to the first gene therapy for deafness

· 3h

Regeneron FDA approval: gene therapy for inherited deafness free

The FDA approved Regeneron's Otarmeni on April 23, making it the first gene therapy for inherited hearing loss — and Regeneron said it will make the treatment available at no cost to eligible patients...

STAT · 1d

Gene therapy trial for deafness adds evidence to drug’s efficacy

Becker's Hospital Review · 1d

Gene therapy restores hearing to 90% of patients in deafness study

Louisiana’s 1st sickle cell gene therapy patient heads home after historic treatment

After six weeks in the hospital, 23‑year‑old Daniel Cressy leaves with hope for a functional cure and a future where he can finally pursue his dream of flying.

$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a functional cure for the deadly blood disorders sickle cell disease and beta

Labiotech.eu

The future of cell & gene therapy: Key trends to watch

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.

Labroots

Cell & Gene Therapy Virtual Event Series 2027

Labroots is pleased to announce the 3rd annual event in the Cell & Gene Therapy Virtual Event Series, taking place on October 13th, 2027. The Cell & Gene Therapy planning committee will invite speakers from industry and academia to discuss key challenges ...

PharmTech

Avi Nandi on How CDMOs Are Simplifying Cell & Gene Supply Chains

Avi Nandi, SK Pharmteco, explains at INTERPHEX 2026 how CDMOs simplify cell & gene therapy supply chains by managing lead times, consistency, and material expiry. Avi Nandi, SK Pharmteco discusses the company's work as a CDMO and the challenges of managing media and buffer supply chains for cell and gene therapy manufacturers in Part 1 of a two-part interview with PharmTech at INTERPHEX 2026.

InVita Healthcare Technologies and Gulf Coast Blood Advance Cell and Gene Therapy Donor Recruitment Through HemaConnect 2.5

InVita Healthcare Technologies, a leader in blood and other biologics software, and Gulf Coast Blood, one of the nation's largest community blood centers, today announced new advanced therapy capabilities developed in collaboration and introduced in InVita's HemaConnect 2.

Managed Healthcare Executive

FDA approves the first gene therapy for genetic hearing loss

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients with biallelic variants in the OTOF gene. The gene therapy will be made available to eligible patients at no cost, according to a news release from Regeneron, the therapy’s developer.